Reimbursement authority NICE published draft guidance today giving a green light to the use of Columvi (glofitamab) in ...

The study of GanLum (KLU156) – a combination of novel drug ganaplacide with established antimalarial lumefantrine – showed ...

FDA Commissioner Marty Makary and Vinay Prasad, director of the Center for Biologics Evaluation and Research (CBER), describe ...

The alliance between AbbVie and Calico dates back to 2014, just a year after it was launched by Alphabet's Google unit, when ...

For the Financial Times (FT) Global Pharma & Biotech Summit in London 2025, pharmaphorum is providing coverage courtesy of ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be ...

Trenton M. Johnson is a seasoned project management leader with 27+ years of experience working in the biopharma industry ...

The LDL-C reductions seen with enlicitide in both studies are in the same ballpark as those seen with injectable ...

The $6.7 billion merger brought together two companies that had been forced to file for bankruptcy protection due to opioid ...

In type 1 diabetes, the CGM has been paired with automated insulin delivery, and we've closed the loop and dramatically changed outcomes for people with type 1 diabetes. ... I believe CGM is the ...

Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 readouts ...

Alkermes already has positive results for alixorexton in NT1 from the phase 2 Vibrance-1, while Takeda is developing another ...